Hypertension during pregnancy, such as preeclampsia, is an important cause of maternal, fetal and neonatal death in the U.S. Women who suffer hypertension in pregnancy are at increased risk of complications during pregnancy as well as post-delivery. The risk of complications arising from hypertension during and after pregnancy disproportionally affects black women, who are much higher risk of morbidity and mortality from preeclampsia compared to white women. We will implement the Systematic Treatment and Management of Postpartum Hypertension (STAMPP-HTN) bundle to women who have recently completed a hypertensive pregnancy. This includes home blood pressure telemonitoring (HBPT) a combination of home blood pressure monitoring coupled with telematic data transmission to a member of the study team, with real-time feedback on patient status and guideline-based postpartum discharge instructions. These ACOG guidelines include education on the importance of blood pressure control and postpartum preeclampsia. We hypothesize that the addition of HBPT to an improved guideline-based hospital discharge will result in improved BP control resulting in less maternal morbidities and improved attendance to the 6-week postpartum visit. To test this central hypothesis, we have developed the following objectives: Objective 1) To determine if HBPT decreases the severity of postpartum hypertension complications we will compare postpartum outcomes (trips to the emergency room, phone calls regarding blood pressure, hospital readmission, severity of any new comorbidities, maternal deaths) between women being monitored to those from the previous year who received no postpartum blood pressure monitoring. Objective 2) To increase awareness and knowledge of postpartum blood pressure control in a group of high-risk women we will administer a 9-question survey before any hypertension education is conducted with study participants and again at the end of the 6-week study. Objective 3) To assess compliance using HBPT and adherence to blood pressure medication (if applicable) in high-risk postpartum women study completion records (per week) will be compared with study covariates (i.e. maternal race, age, parity).